Baldness Drug Shows 500% Improvement in Hair Growth

Male pattern baldness, or androgenic alopecia, is a common type of hair loss affecting men, typically starting in their late 20s and early 30s, according to Cleveland Clinic. This condition causes hair loss on the scalp, and the lost hair doesn’t grow back. Thinning hair and a receding hairline are other common signs.

Numerous studies have investigated male pattern baldness, and many medications have emerged, promising reversal of the condition. However, none have shown meaningful promise until clascoterone.On Wednesday, November 31, 2025, Cosmo Pharmaceuticals, based in Ireland, announced the results of two phase III trials of the drug.

Baldness Drug Shows 500% Improvement in Hair Growth

The trials, published in the Journal of the American Academy of Dermatology, demonstrated a 500% increase in hair growth compared to a placebo. Clascoterone is a topical anti-androgen, meaning it’s applied directly to the scalp and works by blocking the effects of androgen hormones – the primary cause of male pattern baldness.

Researchers found that patients using clascoterone experienced significant increases in hair count and coverage. The drug was also well-tolerated,with minimal side effects reported. “These results are truly remarkable,” said Dr. Antonella Tosti, a lead investigator in the trials. “We haven’t seen this level of efficacy with any other topical treatment for male pattern baldness.”

Cosmo Pharmaceuticals plans to submit clascoterone for regulatory approval in the United States and Europe in early 2026. If approved, it could offer a new and effective treatment option for the millions of men affected by this common condition. The company is also exploring the potential of clascoterone for treating female pattern hair loss.

Key findings:

• 500% increase in hair growth compared to placebo.
• Clascoterone is a topical anti-androgen.
• Minimal side effects reported in trials.
• Regulatory submission planned for 2026.

Source: Cosmo Pharmaceuticals, Journal of the american Academy of dermatology